The world’s pharmaceutical industry continued its trend of consolidation Thursday as Sweden-based drug company Meda announced plans to acquire Italy’s Rottapharm for $3.1 billion.
Reports say the takeover marks the largest merger ever struck in Media’s history.
The pharmaceutical giant had earlier said that it prefers “to eat and not be eaten” in a global market that has seen a wave of M&A activity in recent months. According to reports, Meda has turned down a takeover offer by Mylan, based in the US.
Some industry experts had hoped Mylan would up its bid for the deal, but those hopes were dashed when Mylan acquired a portfolio from rival Abbott earlier last month.
Meda and Rottapharm expect to finalize the deal in the fourth quarter.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI